Transplantation in 2015: Advances in Solid Organ and Blood/Marrow Transplantation
FRIDAY, AUGUST 28 — Up to 5.75 continuing education credits available — ACPE UAN 0860-9999-15-022-L01-P
Recent Advances in Blood/Marrow Transplantation (BMT), Robert Collins, MD
Over the years BMT has been used with increasing frequency to treat numerous malignant and nonmalignant diseases. This session will provide an overview of recent approaches in BMT aimed to reduce toxicity, graft-vs.-host disease (GVHD), and relapse; increase donor availability; and bring precision to patient selection.
Management of Long-Term Survivors of BMT, Madhuri Vusirikala, MD
The long-term care of survivors of blood/marrow transplantation is complex, requiring coordinated care across many disciplines. This session will discuss late complications post blood/marrow transplantation, prevention and management of complications, screening, and follow-up guidelines for long-term survivors of both autologous and allogeneic stem cell transplant.
Integrating Transplantation with Novel Therapies in Myeloma, Larry D. Anderson, MD, PhD
New therapies for multiple myeloma have dramatically improved life expectancy for patients with this disease. This session will provide an overview of myeloma therapy with an emphasis on the role of autologous stem cell transplant (SCT) and sequencing with novel therapies.
Management of Complex Psychosocial Issues in Blood/Marrow Transplantation Patients, Prapti Patel, MD
The psychosocial well-being and quality of life for transplant patients are key long-term goals for the transplant team, along with the prevention of psychosocial barriers and noncompliance-related behaviors. This session will review specific psychosocial issues that transplant patients face and management strategies to help patients overcome them.
Palliative Care, Tamara McGregor, MD
Human Leukocyte Antigen (HLA): Why Is It Important? Chantale Lacelle, PhD, D(ABHI)
HLA matching is an important factor for a successful transplant. This session will provide an overview of the HLA system, explain key terms such as calculated panel reactive antibody (cPRA), donor specific antibody (DSA) and unacceptable antigens. It will also briefly explain how the cPRA is used in organ allocation and how HLA data is used in paired exchanged programs.
ABC of Transplantation in the Setting of New UNOS Allocation System, Miguel Vazquez, MD, and Bekir Tanriover, MD, MPH
The goal of the UNOS organ allocation system is to achieve a balance in organ allocation. This session will review outcomes of renal transplantation over the last decade, implications of the new UNOS deceased-donor kidney transplant allocation system and emerging trends to improve organ shortage.
Living Donor Kidney Transplant, Christine Hwang, MD
Heart/Kidney Transplant Patient, Dana McCullough
These materials are intended ONLY for pharmacists and pharmacy technicians that attended "Transplantation in 2015: Advances in Solid Organ and Blood/Marrow Transplantation" held in Dallas, Tex., on Aug. 28, 2015.
The prerequisite to this process is completing the Transplantation in 2015: Advances in Solid Organ and Blood/Marrow Transplantation's Conference Post-Assessment and Evaluation. If there is a Prerequisite section above and the Status field is blank, click on 'Transplantation in 2015: Advances in Solid Organ and Blood/Marrow Transplantation' to open the Assessment and Evaluation.
- 5.75 ACPE - Pharmacist